TerbinafineHydrochloride
Read this package insert carefully before starting to take this medication,because it contains important information for you.
Terbinafine belongs to a group of medicines called antifungals and works by preventing the development of fungi.
Lamisil is used to treat the following fungal skin, scalp, and nail infections:
Tinea corporis(body ringworm).
Tinea cruris(inguinal ringworm or jock itch).
Tinea pedis(athlete's foot).
Tinea capitis(scalp ringworm).
Onychomycosis (nail ringworm).
Read the following information before taking Lamisil tablets.
Do not take Lamisil tablets
Warnings and precautions
Consult your doctor or pharmacist before starting to take Lamisil tablets.
If any of these conditions affect you, inform your doctor before taking Lamisil.
This medicine contains less than 23 mg of sodium (1 mmol) per tablet; it is essentially "sodium-free".
Use in children
The experience with Lamisil tablets in children is limited, therefore, it is not recommended for use in this type of patient.
Lamisil tablets can be administered to patients over 65 years of age. If there is a pre-existing renal problem, you may be prescribed a lower than usual dose.Lamisil is not recommended for patients who have or have had liver problems.
Other medicines and Lamisil tablets
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medicine, including oral contraceptives, herbal medicines, and those obtained without a prescription. There are other medicines that may modify the effect of Lamisil tablets, for example:
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medicine.
You can use Lamisil tablets during pregnancy only if your doctor tells you to.
A small amount of terbinafine is transferred to breast milk. If you are breastfeeding, consult your doctor before using Lamisil tablets.
If you feel dizzy while taking Lamisil tablets, do not drive or operate machinery.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
Remember to take your medication.
Take Lamisil tablets as directed by your doctor. He will determine the dose you need.
The usual dosein adults is one tablet (250 mg) once a day.
Lamisil tabletsare oral tablets. Swallow the tablets whole, without chewing, with a glass of water.
The duration of treatment will be established by your doctor. Do not stop treatment before, as it may worsen your condition.
It is possible that the complete resolution of symptoms of the infection will not occur until several weeks (skin and scalp) or months (nails) after the disappearance of the fungus causing the infection.
If you take more Lamisil tablets than you should
Consult your doctor, pharmacist, or callthe Toxicological Information Service (phone 91 562 04 20)indicating the medication and the amount used.
The main symptoms of acute poisoning may be gastrointestinal, e.g. nausea, abdominal pain, or vomiting, but may also present with headache or a sense of instability (dizziness). If you experience any of these effects or any other unusual effect, consult your doctor.
If you forgot to take Lamisil tablets
Take another one as soon as you remember, unless it is less than 6 hours before the next dose.
Do not take a double dose to compensate for the missed doses.
Some side effects can be severe:
Rarely, Lamisil tablets may cause problems in the liver and in very rare cases these problems can be severe. Severe adverse reactions also include a decrease in certain blood cells, lupus (an autoimmune disease), severe skin reactions, severe allergic reactions, inflammation of blood vessels, pancreatitis or muscle necrosis.
Stop taking this medicine and inform your doctor immediately:
Rare:may affect up to 1 in 1,000 people
Veryrar:may affect up to 1 in 10,000 people
Unknown frequency:cannot be estimated from available data
Otherside effects
Other side effects include the following listed below. If they become severe, inform your doctor, pharmacist or nurse.
Most side effects are mild or moderate and usually disappear after a few days to a few weeks of treatment.
Very common(may affect more than 1 in 10 people):
Headache, nausea, mild abdominal pain, postprandial gastric discomfort (heartburn), diarrhea, abdominal distension or bloating (feeling of fullness in the stomach), loss of appetite, skin rash (with itching), urticaria, joint or muscle pain.
Common(may affect up to 1 in 10 people):
Mood disorder (depression), taste disturbance or loss, dizziness, visual disturbances.
Uncommon(may affect up to 1 in 100 people):
Pale skin, abnormal mucous membrane or nail bed, unusual fatigue or weakness, or difficulty breathing during exercise (possible signs of a disease affecting red blood cell levels), anxiety, sensation of tingling or numbness and decreased skin sensitivity, increased skin sensitivity to the sun, ringing in the ears, fever andweight loss.
Rare(may affect up to 1 in 1,000 people):
Abnormal liver function test results.
Very rare(may affect up to 1 in 10,000 people):
Psoriasis-like skin eruptions (skin rash with silver appearance), worsening of psoriasis, and skin eruption with peeling and hair loss.
Unknown frequency(cannot be estimated from available data):
Changes in smell including permanent loss, decreased ability to smell, blurred vision, decreased visual acuity, hearing loss or difficulty hearing, skin rash caused by elevated levels of a specific type of white blood cell, pseudo-gripal symptoms (e.g. fatigue, chills, sore throat, muscle or joint pain), and increased blood levels of a muscle enzyme (creatine phosphokinase).
If you notice any side effect not mentioned in this leaflet, inform your doctor or pharmacist.
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use: www.notificaRAM.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Store in the original packaging.
Do not store this medication in a warm place.
Store the tablets protected from light.
Do not use this medication after the expiration date that appears on the packaging.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection point at the pharmacy. Ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Lamisil tablets
Appearance of the product and contents of the packaging
Lamisil tablets are scored, circular, biconvex, white to light yellowish in color, and have the inscription LAMISIL 250 in a circular pattern on one face.They are available in packs of 14 and 28 tablets.
Other presentations:
Lamisil 10 mg/g cream. Pack with 30 g.
Lamisil 10 mg/g topical solution. Pack with 30 ml.
Lamisil 10 mg/g topical solution for skin spray. Pack with 30 ml.
Novartis Farmacéutica, S.A.
Gran Vía de les Corts Catalanes, 764
08013 – Barcelona
Spain
Responsible for manufacturing
Novartis Farmacéutica, S.A.
Gran Vía de les Corts Catalanes, 764
08013 – Barcelona
Spain
Lek d.d, PE PROIZVODNJA LENDAVA
Trimlini 2D
Lendava, 9220
Slovenia
Novartis Pharma GmbH
Roonstrasse 25
90429 Nürnberg
Germany
Last review date of this leaflet:March 2024
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.